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Introduction
In recent years, infections caused by multi-drug resistant 
(MDR) pathogens have become a serious problem, 
especially in the nosocomial setting. Th  e World Health 
Organization (WHO) has identiﬁ  ed antimicrobial resis-
tance as one of the three most important problems for 
human health. Some authors have summarized this 
pheno  menon with the word ‘ESKAPE’, to include the 
most frequent MDR microorganisms: Enterococcus 
faecium, Staphylococcus aureus, Klebsiella pneumoniae, 
Acinetobacter baumannii, Pseudomonas aeruginosa and 
Enterobacter spp. [1]. Resistance to the current library of 
antibacterial drugs is a serious problem in all parts of the 
world including the Asia-Paciﬁ  c region, Latin America, 
Europe, and North America.
Numerous classes of antimicrobials are currently 
available for physicians to use in the treatment of patient 
with infections; however, the pace of antibiotic drug 
development has slowed during the last decade (Fig. 1). 
In particular, the pharmaceutical pipeline of antibiotics 
active against MDR Gram-negative bacteria is very 
limited. New antibiotics that have been discovered and 
introduced into clinical practice in the last few years are 
active mostly against Gram-positive organisms, whereas 
when targeting resistant Gram-negative bacteria, clini-
cians are forced to rediscover old drugs, such as poly-
mixins and fosfomycin. Among new antibacterials active 
against Gram-negative microorganisms that are already 
on the market, tigecycline, the ﬁ   rst Food and Drug 
Administration (FDA)-approved representative of the 
glycylcyclines, and doripenem, a new carbapenem, seem 
the most promising.
Since 2001, diﬀ  erent agencies and societies have tried 
to draw attention to the signiﬁ  cant lack of new antibiotics 
for Gram-negative pathogens. In fact, in 2004 the 
Infectious Diseases Society of America (IDSA) issued 
their report, “Bad Bugs, No Drugs: As Antibiotic Dis-
covery Stagnates, A Public Health Crisis Brews,” which 
proposed incentives to reinvigorate pharmaceutical 
investment in antibiotic research and development [2]. In 
2007, the IDSA and the FDA repeated their call for an 
increase in new antibacterial research to develop next-
generation drugs [3]. Recently, the IDSA supported an 
initiative of developing 10 new systemic antibacterial 
drugs through the discovery of new drug classes, as well 
as exploring possible new molecules from existing classes 
of antibiotics (the “10 x ‘20” initiative, endorsed by the 
American Academy of Pediatrics, American Gastro-
entero  logical Association, Trust for America’s Health, 
Society for Healthcare Epidemiology of America, Pedia-
tric Infectious Disease Society, Michigan Antibiotic 
Resis  tance Reduction Coalition, National Foundation for 
Infectious Diseases, and European Society of Clinical 
Microbiology and Infectious Diseases) [4].
Th  e  proﬁ  le of resistance to currently used antimicrobial 
agents and the development of new anti-Gram-negative 
agents, with a particular attention to cephalosporins, β-
lactamase inhibitors and carbapenems will be discussed.
Mechanism of resistance to currently used 
antimicrobial agents in multi-drug resistant 
gram-negative bacteria
β-lactamase-mediated resistance is the most important 
and eﬃ   cient method of β-lactam resistance for Gram-
negative bacteria. Th  e origin of β-lactamases is presu-
mably ancient and their development evolved to combat 
natural β-lactams. However, resistance has been heavily 
inﬂ   uenced over the years by the widespread adminis-
tration of these antibiotics in clinical practice. For 
example, the rapid increase in resistance to the widely-
used ampicillin in the early 1960s turned out to be due to 
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under the German Copyright Law.a plasmid-mediated β-lactamase, one of the ﬁ  rst 
described in Gram-negative bacteria, known as TEM (the 
TEM 1 enzyme was originally found in Eschericihia coli 
isolated from a patient named Temoniera, hence named 
TEM). Th  e further selection of resistant mutants led to 
the appearance of extended-spectrum β-lactamases 
(ESBLs) that now compromise the use of even third-
generation cephalosporins. In the 1990s, the pharma-
ceutical industry introduced carbapenems, which are 
extremely stable to degradation by β-lactamases. How-
ever, a variety of β-lactamases that are capable of hydro-
lyzing these antibiotics, including imipenemase (IMP), 
Verona integron-encoded MBL (VIM), K. pneumoniae 
carbapenemase (KPC) and oxacillinase (OXA) are being 
increasingly seen in Gram-negative bacterial isolates.
Diﬀ  erent  classiﬁ   cations of β-lactamases have been 
proposed, but the Ambler classiﬁ   cation is the most 
widely used and divides β-lactamases into four classes (A, 
B, C and D) based upon their amino acid sequences 
(Table  1) [5,6]. Brieﬂ   y, class A enzymes are plasmid-
mediated penicillinases, constitutively expressed and sus-
ceptible to inhibition by β-lactamase inhibitors; repre-
sen  tative enzymes include TEM and sulfhydryl reagent 
variable (SHV) subclasses. Some evolved class A β-
lactamases accept extended-spectrum cephalosporins as 
substrates and are known as ESBLs, even if there are 
ESBL enzymes belonging to other classes as well. Class B 
enzymes are metallo-β-lactamases (MBL) with broad 
substrate speciﬁ  city that includes not only penicillins and 
cephalosporins, but also carbapenems. Class C enzymes 
are primarily chromosomally encoded cephalosporinases 
and are often referred to as AmpC β-lactamases resistant 
to inhibition by β-lactamase inhibitors. Finally, class D β-
lactamases have a substrate preference for oxacillin and 
are therefore called oxacillinases. Th   is class diversity is a 
crucial aspect for antimicrobial therapy. Recently, a new 
plasmid MBL, the New Delhi MBL (NDM-1) was identi-
ﬁ  ed  in  K. pneumoniae and E. coli recovered from a 
Swedish patient who was admitted to hospital in New 
Delhi, India [7]. Of particular concern is that NDM 
enzymes are present in E. coli, the most common cause of 
community-associated urinary tract infections. Th  e 
NDM-producing bacteria are resistant to many groups of 
antibiotics, including ﬂ  uoroquinolones, aminoglycosides, 
and β-lactams (especially carbapenems), and are suscep-
tible only to colistin and tigecycline [7]. Nevertheless, 
even these two agents might lose their activity.
Th   e target of the antimicrobial action of colistin is the 
bacterial cell membrane and studies on colistin-resistant 
P. aeruginosa strains have reported alterations at the 
outer membrane of the cell, leading to resistance [8]. 
Th  us, colistin might not be a long-standing treatment 
option for MDR Gram-negative bacteria. As far as 
resistance to tigecycline is concerned, low concentrations 
attained in the serum are probably the driving force for 
the development of resistance while on treatment, 
particularly when the minimum inhibitory concentra-
tions (MICs) of the targeted pathogen exceed the Cmax 
of the drug, which is almost the rule for all targeted A. 
baumannii strains [9]. Th   e genetic basis of development 
of resistance has been investigated with molecular studies 
and eﬄ     ux pumps seem to be the most important 
mechanism of decreased susceptibility. Various eﬄ   ux 
pumps have been reported in E. coli, E. cloacae,  K. 
pneumoniae and A. calcoaceticus-A. baumannii [10].
Gram-negative resistant bacteria and drug 
development needs
Given the continuous increase in antibiotic resistance, the 
IDSA’s Antimicrobial Availability Task Force identi  ﬁ  ed 
development needs for the ESKAPE pathogens, includ  ing 
Gram-negatives such as E. coli, Klebsiella spp.,  Entero-
bacter spp., P. aeruginosa and Acinetobacter spp. [1,11].
In  Enterobacteriaceae, the main resistance problems 
stem from production of ESBL, inducible chromosomal 
cephalosporinases and carbapenemases, including K. 
pneumoniae carbapenemase (KPC)-hydrolyzing β-lacta-
mases [12]. Infections due to ESBL-producing E. coli and 
Klebsiella  spp. continue to increase in frequency and 
severity. In an interesting meta-analysis of 16 studies, 
bacteremias caused by ESBL-producing pathogens were 
signiﬁ  cantly associated with delayed initiation of eﬀ  ective 
therapy and increased crude mortality [13]. Additionally, 
Enterobacter causes an increasing number of health care-
associated infections and is increasingly resistant to 
multiple antibacterials [12]. Enterobacter infections, 
especially bloodstream infections, are associated with 
signiﬁ  cant morbidity and mortality [14]. Unfortunately, 
drugs in late stage development, as well as the recently 
approved doripenem, oﬀ  er little advantage over already 
existing carbapenems for treating infections due to 
ESBL-producing bacteria. Moreover, carbapenem-
resistant Enterobacteriaceae are increasingly recognized 
Figure1. New antibacterial agents approved in the United 
States, 1983–2009. From [3] with permission.
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wide [15,16]. Th  us, tigecycline and the polymyxins, 
including colistin, have been used with variable success 
rates and there are currently no antibacterials in ad-
vanced development for these highly resistant pathogens 
[17]. Aggressive infection-control practices are required 
to abort epidemic outbreaks.
Rates of infection by resistant P. aeruginosa continue to 
increase in the United States and globally, as does 
resistance to β-lactams, quinolones, aminoglycosides, 
and carbapenems [18]. Resistance of P. aeruginosa to 
polymyxins has also been reported. Patients at risk 
include those in the intensive care unit (ICU), particularly 
if they are ventilator dependent, and individuals with 
cystic ﬁ  brosis. To date, no drug in clinical development 
addresses the issue of MDR or oﬀ   ers a less toxic 
alternative to the polymyxins for treating P. aeruginosa.
Last but not least, the incidence of infections due to 
MDR Acinetobacter spp. continues to increase globally 
[19]. Unfortunately, no agents against Acinetobacter spp. 
are under development and infections caused by this 
patho  gen are emblematic of the mismatch between 
unmet medical needs and the current antimicrobial 
research and development pipeline.
New β-lactamase inhibitors
In β-lactam agent/β-lactamase inhibitor combinations, 
the latter agent potentates the action of the former by 
protecting it from enzymatic hydrolysis. Currently used 
β-lactam/β-lactamase inhibitor compounds are highly 
active against class A and various ESBLs, whereas activity 
against class C and class D enzymes is poor [20,21].
Several compounds are now under investigation as 
potential β-lactamase inhibitors, in diﬀ   erent stages of 
pre-clinical and clinical studies. Th   ey can be classiﬁ  ed as 
β-lactams and non-β-lactams according to their 
molecular structure. Th   eir main advantage over the older 
β-lactamase inhibitors is conferred by their ability to 
Table 1. Classifi  cation schemes for bacterial β-lactamases.
Bush-      
Jacoby Molecular     
group   class     
(2009)   (subclass)  Distinctive substrate(s)  Defi  ning characteristic(s)  Representative enzyme(s)
1  C  Cephalosporins  Greater hydrolysis of cephalosporins than benzylpenicillin;   E. coli AmpC, P99, ACT-1, CMY-2, 
      hydrolyzes cephamycins  FOX-1, MIR-1
1e  C  Cephalosporins  Increased hydrolysis of ceftazidime and often other   GC1, CMY-37
     oxyimino-β-lactams
2a  A  Penicillins  Greater hydrolysis of benzylpenicillin than cephalosporins  PC1
2b  A  Penicillins, early  Similar hydrolysis of benzylpenicillin and cephalosporins  TEM-1, TEM-2, SHV-1
   cephalosporins
2be  A  Extended-spectrum   Increased hydrolysis of oxyimino-β-lactams (cefotaxime,   TEM-3, SHV-2, CTX-M-15, PER-1, 
    cephalosporins,   ceftazidime, ceftriaxone, cefepime, aztreonam)  VEB-1
   monobactams
2br  A  Penicillins  Resistance to clavulanic acid, sulbactam, and tazobactam  TEM-30, SHV-10
2ber  A  Extended-spectrum   Increased hydrolysis of oxyimino-β-lactams combined with  TEM-50
    cephalosporins,   resistance to clavulanic acid, sulbactam, and tazobactam 
   monobactams   
2c  A  Carbenicillin  Increased hydrolysis of carbenicillin  PSE-1, CARB-3
2ce  A  Carbenicillin, cefepime  Increased hydrolysis of carbenicillin, cefepime, and cefpirome  RTG-4
2d  D  Cloxacillin  Increased hydrolysis of cloxacillin or oxacillin  OXA-1, OXA-10
2de  D  Extended-spectrum   Hydrolyzes cloxacillin or oxacillin and oxyimino-β-lactams  OXA-11, OXA-15
   cephalosporins
2df  D  Carbapenems  Hydrolyzes cloxacillin or oxacillin and carbapenems  OXA-23, OXA-48
2e  A  Extended-spectrum   Hydrolyzes cephalosporins. Inhibited by clavulanic acid but  CepA
 `  cephalosporins  not  aztreonam 
2f  A  Carbapenems  Increased hydrolysis of carbapenems, oxyimino-β-lactams,   KPC-2, IMI-1, SME-1
     cephamycins
3a  B (B1)  Carbapenems  Broad-spectrum hydrolysis including carbapenems but   IMP-1, VIM-1, CcrA, IND-1
     not  monobactams
  B (B3)      L1, CAU-1, GOB-1, FEZ-1
3b  B (B2)  Carbapenems  Preferential hydrolysis of carbapenems  CphA, Sfh-1
NI Unknown     
Adapted from [5].
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currently used β-lactams, such as piperacillin or cefta-
zidime, is decreased when administered together with a 
novel β-lactam inhibitor, and these antibiotics become 
active against ESBL-producing strains. Moreover, their 
combined use with carbapenems, makes the latter active 
against MBL-producing strains.
Although the results of studies on the clinical 
usefulness of new β-lactam inhibitors are not yet 
available, they seem particularly promising as therapeutic 
agents. Details of new β-lactam inhibitors are outlined in 
Table 2.
Inhibitors with a β-lactam structure
Imidazole-substituted 6-methylidene-penem molecules
Th   e unique structure of these compounds (they contain 
byciclic or triciclic substituents connected by a methy-
dilene linkage to the 6 position of the β-lactam ring) 
imparts potent activity against class A and C β-
lactamases, such as the AmpC enzyme, which is not 
observed with the currently used inhibitors. Several 
novel compounds demonstrated excellent in vitro inhibi-
tion of the TEM-1 enzyme (class A β-lactamases) and 
AmpC enzyme with signiﬁ   cantly higher activity com-
pared with tazobactam [22]. In vitro tests showed 
synergistic activity of these compounds when combined 
with piperacillin with susceptibility of 90% of the tested 
organisms; animal models conﬁ   rmed the synergistic 
eﬀ   ect with piperacillin [22,23]. Among these agents, 
BLI-489 is the compound with the most promising 
clinical data. It has shown activity against molecular class 
A, C and D enzymes, including ESBL as well as class C β-
lactamases; some strains that were class C or ESBL 
producers, classiﬁ  ed as non-susceptible to piperacillin/
tazobactam, were found to be susceptible to piperacillin/
BLI-489 [24].
2β-alkenyl penam sulfones
2β-alkenyl penam sulfones, another group of inhibitors 
with β-lactam structure, inhibit most of the common 
types of β-lactamases, with a level of activity depending 
strongly on the nature of the substituent in the 2β-alkenyl 
group. Richter et al. demonstrated that Ro 48-1220, the 
most active inhibitor from this class of compounds, 
enhanced the action of ceftriaxone against a broad 
selection of organism producing β-lactamases, including 
strains of cephalosporinase-producing Enterobacteriaceae 
[25]. In a diﬀ  erent study, Ro 48-1220 was at least 15 times 
more eﬀ   ective than tazobactam against the class C 
enzymes and reduced the MIC values of ceftriaxone and 
ceftazidime against the class A plasmid-mediated β-
lactamases; less potency was exerted towards SHV-type 
β-lactamases [26].
4-phenyl cyclic phosphate
4-phenyl cyclic phosphate is a monocyclic acyl phos-
phonate. It has an irreversible reaction with E. Cloacae 
P99 β-lactamase (Class C). Th  is compound also bound 
TEM-2 and P99 β-lactamases non-covalently. Similar to 
other novel inhibitors, it is eﬀ  ective against class A and 
class C enzymes [27].
C3-modifi  ed penicillin sulfones
Buynak et al. reported that C3-methylene-group peni  cil-
lin sulfones were 10-fold more active against class C β-
lactamases compared to sulbactam [28].
Table 2. Old and new β-lactamase inhibitors and specifi  c activity against diff  erent classes of β-lactamases
Inhibitor  Class A  Class B  Class C  Class D  FDA Status
Inhibitors with β-lactam structure
 Clavulanic  acid  ++  –  +  +  Approved
 Tazobactam  ++  –  +  +  Approved
 Sulbactam  ++  –  +  +  Approved
 BLI-489  ++  UA    ++  ++  Pre-clinical
  Ro 48–1220  +++  UA   ++  UA  Pre-clinical
  4-phenyl cyclic phosphate  +++  UA   ++  UA  Pre-clinical
  C3-methylene-modifi  ed group penicillin sulfone  UA  UA   ++  UA  Pre-clinical
 BAL  30376  UA  +  ++  UA  Pre-clinical
 LK-157  ++  UA    UA  UA  Pre-clinical
 Oxapenems  ++  UA    ++  ++  Pre-clinical
Inhibitors without β-lactam structure
  NXL104  +++ +  ++ ++  Phase  II
  ME1071  UA ++ UA UA  Pre-clinical
UA, unknown activity; FDA: Food and Drug Administration
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BAL 30376 is a β-lactamase inhibitor and is a combi-
nation of BAL 0019764 (a siderophore monobactam), 
BAL 0029880 (a bridged monobactam which is a class C 
inhibitor), and clavulanic acid [24]. Page et al. [29] 
demonstrated the in vitro activity of BAL 30376 against 
various Gram-negative bacteria. MICs were observed in 
a range of ≤ 0.06–4 mg/l, including most carbapenem-
resistant strains. Higher MICs were observed for a few 
strains of Acinetobacter spp., Enterobacter spp. and P. 
aeruginosa.
Tricyclic carbapenem inhibitors
LK-157 is a tricyclic carbapenem inhibitor of serine β-
lactamases [24]. LK-157 decreased the MICs of aztreo-
nam, ceftazidime, and cefuroxime for B. fragilis and a 
wide range of β-lactamases-producing Enterobacteria-
ceae members. However, LK-157 did not affect the 
MICs of aztreonam, ceftazidime or cefuroxime against 
CTX-M producing members of Enterobacteriaceae 
[24].
Oxapenems
Four β-lactamase inhibitors, members of the oxapenems, 
are being developed (AM-112 – AM-115) and express 
activity against class A, C, and D enzymes [30]. AM-114 
and AM-115 displayed the most potent activity against 
class A enzymes, comparable to that of clavulanic acid. 
Activity against class C and class D enzymes was similar 
to that of AM-112 and AM-113 and was superior to that 
of clavulanic acid. A synergistic activity of ceftazidime 
with the oxapenems was demonstrated against SHV- and 
TEM-producing E. coli. Enhanced activity of oxapenems 
in combination with ceftazidime was also noted against 
Pseudomonas strains and MRSA [31].
Inhibitors with no β-lactam structure
NXL104
NXL104 is a non-β-lactam compound which inhibits β-
lactamases through the formation of a stable covalent 
carbamoyl linkage. In combination with ceftazidime 
and cefotaxime against Enetrobacteriaceae producing 
CTX-M ESBLs, it showed a 4 to 8000-fold potentiation 
of the cephalosporins, with MIC values ≤ 1 for all 
organisms irrespective of CTX-M type [24]. Against 
P99, NXL104 showed a stronger inhibition than 
tazobactam, whereas clavulanic acid was inactive. 
Another study showed that combination with NXL104 
restored the activity of ceftazidime and cefotaxime 
against isolates producing class A carbapenemases [24]. 
NXL104/ceftazidime combi  nation is currently under-
going Phase II clinical trials in patients admitted for 
complicated intra-abdominal and complicated urinary 
tract infections [32].
Maleic acid derivates
ME1071, previously known as CP3242, is a metallo β-
lactamase inhibitor that competitively inhibits IMP-1 and 
VIM-2. It signiﬁ  cantly lowered the MICs of biapenem in 
a concentration-dependent manner against MBL-
produc ing  P. aeruginosa. MIC lowering by ME1071 was 
also shown for IMP- or VIM-producing E. coli, S. marces-
cens, A. baumanii and K. pneumoniae [24].
New cephalosporins
New cephalosporins are very resistant to penicillinases 
and two of them have demonstrated anti-methicillin 
resistant S. aureus (MRSA) activity in animal mod els of 
infections. Some of these compounds also showed potent 
anti-Gram-negative activity. However, there is no 
evidence of better activity against MDR Gram-negative 
bacteria compared to older cephalosporins.
Ceftobiprole
Ceftobiprole (formerly BAL-9141) is the active compo-
nent of the prodrug ceftobiprole medocaril (formerly 
BAL-5788), and represents a novel cephalosporin with 
expanded activity against Gram-positive bacteria. It has 
been engineered to bind highly to penicillin binding 
protein 2a (PBP2a). Ceftobiprole is stable against some 
enzymes (non-ESBL class A), but is hydrolyzed by ESBLs 
and carbapenemases [33]. A study published in 2008 
reported that ceftobiprole monotherapy was as eﬀ  ective 
as vancomycin combined with ceftazidime for treating 
patients with a broad range of complicated skin and skin-
structure infections and infections due to Gram-positive 
and Gram-negative bacteria [32]. Ceftobiprole is an 
eﬀ  ective anti-MRSA agent that also has activity against 
important Gram-negative bacteria, but there is no 
evidence that ceftobiprole has better activity against class 
A and class C β-lactamase-producing Gram-negative 
bacteria compared to ceftazidime.
Ceftaroline
Ceftaroline is a novel semisynthetic anti-MRSA cephalo-
sporin with broad-spectrum activity, which is currently 
undergoing Phase III clinical trials [35]. Ceftaroline 
maintains good activity against Gram-negative patho-
gens: MIC values were 0.06–0.5 for E. coli,  Klebsiella 
spp.,  M. morganii and Proteus, and 0.12–1  mg/l for 
Entero bacter,  Serratia and Citrobacter spp. MIC value 
rose to 1–2  mg/l for many Enterobacteriaceae with 
classical TEM β-lactamases and were much higher for 
those with ESBL, hyperproduced AmpC or K1 enzymes. 
Ceftaroline selected AmpC-derepressed Enterobacter 
mutants. Similar to cefotaxime in single-step experi-
ments, in multistep procedures it selected ESBL variants 
of TEM [36]. Another study showed that ceftaroline was 
synergistic with the β-lactamase inhibitor, tazobactam, 
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such as ESBL-producing E. coli and K. pneumoniae [37].
Despite being active against resistant Gram-positive 
bacteria, ceftaroline was less active than currently used 
antimicrobial agents against Gram-negatives. A combi-
nation of vancomycin plus aztreonam demonstrated 
higher favorable microbiological response rates than did 
ceftaroline monotherapy against Gram-negative infec-
tions. Th  e eﬃ     cacy of ceftaroline against non-ESBL-
produc ing  E. coli and K. pneumoniae was comparable to 
that of aztreonam; however, the eﬃ   cacy of aztreonam 
against P. aeruginosa and Proteus mirabilis infection was 
better than that of ceftaroline [38].
New carbapenems
Carbapenems are a class of broad-spectrum β-lactams 
identiﬁ  ed in the late 1970s. Th  e main advantage of this 
class of antibiotics is their stability to hydrolysis by many 
ESBLs. At present, meropenem and imipenem/cilastatin 
are widely used and are recommended for treatment of 
several nosocomial infections such as pneumonia (if 
MRSA is excluded), complicated urinary tract infections, 
complicated intra-abdominal infections, febrile neutro-
penia, septicemia, complicated skin and skin-structure 
infections and meningitis. Imipenem is hydrolyzed by 
renal dehydropeptidase I (DHP-I) and this process pro-
duces a nephrotoxic compound; consequently cilastatin, 
the DHP-I inhibitor without antibacterial activity, is 
always co-administered with imipenem in a 1:1 ratio. 
Other carbapenems do not require DHP-1 inhibitors.
Th  ree mechanisms of acquired resistance to carba-
penems are known: 1) structural changes in PBPs; 2) 
carba  penemases; and 3) changes in membrane permea-
bility through the loss of speciﬁ  c porins [39].
Over ten novel compounds are reported in diﬀ  erent 
phases of clinical development; two of them are currently 
marketed and available (ertapenem and doripenem), 
others are in phase II clinical trials while several are still 
being investigated in pre-clinical studies (Table  3). Of 
note, two of the novel carbapenems are developed to be 
administered orally.
Ertapenem
Ertapenem was licensed in the US in 2001 and in Europe 
in 2002. Its main indications include: Intra-abdominal 
infections, complicated skin and skin-structure infec-
tions, complicated urinary tract infections, acute pelvic 
infections and community acquired pneumonia. Th  e 
most important pharmacokinetic feature of this drug is 
due to its net negative charge that increases its binding to 
plasma proteins (95%), which results in a long half-life 
permitting once-daily administration [40]. Th  e main 
limita  tion of ertapenem is its limited activity against non-
fermenting Gram-negative bacteria, such as P. aeruginosa, 
Acinetobacter spp. and B. cepacia [40]. Even though its 
activity against Gram-negative ESBL-producers seems to 
be lower than other carbapenems, ertapenem is approved 
for the treatment of infections caused by these bacteria. 
All three above-mentioned mechanisms of acquired 
resistance to carbapenems have been reported for 
ertapenem [40]. Th   e role of ertapenem in the treatment 
of ventilator-associated pneumonia (VAP) was investi-
gated in a pilot study, which reported that ertapenem was 
useful for treating early-onset VAP due to ESBL-
producers, with clinical success achieved in 80% of 
patients and microbiological success in 75% of cases [41].
Doripenem
Doripenem is a new broad-spectrum, parenteral carba-
penem with a chemical structure that confers β-lacta-
mase stability and resistance to inactivation by renal 
DHP-I. It is as active as imipenem or ertapenem against 
Gram-positive cocci (methicillin-susceptible S. aureus 
[MSSA] and coagulase negative staphylococci), but anti-
Gram-negative activity is similar to that of meropenem, 
and two to three fold superior to imipenem [42]. 
However, doripenem has no activity against MRSA, E. 
fecium, some strains of Burkholderia spp. and Stenotro-
phomonas maltophilia [42]. In an extensive study, in 
which the activity of 24 antibiotics was tested against 394 
strains, doripenem was fully active against AmpC and 
other ESBL-producing Enterobacteriaceae [43]. Addi-
tion  ally, doripenem was found to be more active against 
Acinetobacter  spp. and P. aeruginosa when the same 
susceptible and intermediate concentrations were used 
for imipenem and meropenem. Other strains that 
remained inhibited by doripenem concentrations 
≤ 4 microg/ml were penicillin-resistant streptococci, H. 
inﬂ  uenzae with all resistance patterns tested, and many 
Enterobactericeae resistant to other carbapenems 
because of outer membrane protein alterations, hyper-
expression of AmpC or acquisition of a Bush group 2f 
carbapenemase [43]. At a dose of 500 mg every 8  h, 
doripenem is eﬀ   ective against strains with a MIC 
<  2  mg/l and dose adjustment is required only when 
creatinine clearance is <  30  ml/min. In vivo animal 
studies demonstrated that the incidence of seizures with 
doripenem was lower than with other carbapenems and 
at the recommended dosage the most frequent adverse 
events are nausea (3.7%) and diarrhea (2.5%).
Biapenem
Biapenem is a new parenteral agent that was approved in 
Japan in 2002 and it is currently undergoing phase II 
clinical studies in the USA. Th   e prominent feature of this 
new carbapenem is related to its high concentration in 
respiratory tissue and other body ﬂ  uids. Biapenem has a 
broad spectrum of activity including against Gram-positive 
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strains), MSSA and Gram-negatives including A. bau-
mannii, ESBL-producing Enterobacteriaceae, E. cloacae, 
S. marcescens and Citrobacter freundii. Moderate activity 
with median MIC of 8  mg/l was found against P. 
aeruginosa [44]. Biapenem has a mean plasma half-life of 
one hour and it is recommended at a dosage of 300 mg 
twice daily. It requires an adjustment in case of reduced 
glomerular ﬁ   ltration rate. Biapenem is generally well 
tolerated and clinical trials reported the incidence of 
adverse events ranging from 1.9% to 3.4% with nausea, 
skin eruption, vomiting and diarrhea as the most 
common side eﬀ  ects [45].
Panipenem/betamipron
Th  e combination of panipenem with betamipron, like 
imipenem/cilastatin, is necessary because betamipron 
inhibits the renal uptake of panipenem. Th  is  combination 
is approved in Japan, China and Korea for the treatment 
of lower respiratory tract infections, urinary tract infec-
tions, obstetric/gynecological infections, and surgical 
infections at a dosage of 0.5/0.5 g twice daily as an intra-
venous infusion over 30–60 mins. Th   e clinical eﬃ   cacy of 
panipenem/betamipron was demonstrated in three large, 
randomized, phase III clinical trials comparing this drug 
with imipenem/cilastatin in adults with respiratory and 
urinary tract infections [46–48]. Panipenem’s spectrum 
of activity includes Enterobacteriaceae and common res-
piratory tract pathogens, although meropenem remains 
the most active carbapenem against H. inﬂ  uenzae [49]. 
Panipenem is not active against E. faecium and S. 
maltophilia, and P. aeruginosa seems to be resistant, 
showing MIC90 values of 12.5–25 mg/l [49].
Tebipenem
Tebipenem pivoxil is a prodrug of an oral carbapenem 
with a high degree of stability to DHP-I and absorption of 
the active metabolite into the blood from the intestine. 
While tebipenem is inactive against MBL-producing 
pathogens and MRSA, good activity against penicillin-
susceptible and penicillin-resistant S. pneumoniae, S. 
pyogenes, H. inﬂ  uenzae, K. pneumoniae, M. catarrhalis 
and E. coli has been reported. It is likely to become a 
speciﬁ  c antibiotic for the treatment of persistent otitis 
media, upper respiratory infection and bacterial pneu-
monia in pediatric patients [50]. Phase II clinical studies 
are being conducted in Japan.
Tomopenem
Tomopenem is a novel 1-methyl carbapenem which 
inhibits the activity of PBP and disrupts bacterial cell wall 
peptidoglycan biosynthesis. Tomopenem seems to have a 
very low rate of spontaneous emergence of resistance. In 
vitro activity against β-lactam susceptible and resistant 
strains, including MRSA, ceftazidime-resistant P. aeru-
ginosa and ESBL-producing Enterobacteriaceae has been 
demonstrated [51].
Other new carbapenems
Several novel compounds, still in pre-clinical phases of 
evaluation, are mentioned below, highlighting the results 
of in vitro studies aimed to deﬁ  ne the activity spectrum 
of these new molecules.
1. Th  e group of 2-(thyazol-2-ylthio)-1β-methyl carba-
penems includes SM-197436, SM-232721 and SM-
232724. Th   ese molecules are characterized by a unique 
4-substituted thiazol-2-ylthio moiety at the side chain. 
Th   ey exhibit potent anti-MRSA activity but they have 
insuﬃ   cient activity against E. faecium. As far as Gram-
negative bacteria are concerned, these three carba-
penems are highly active against H. inﬂ  uenzae 
(including ampicillin-resistant strains), M. catarrhalis, 
and B. fragilis, and show antibacterial activity equiva-
lent to that of imipenem for E. coli, K. pneumoniae and 
Table 3. FDA status and pharmacokinetic characteristics of new carbapenems.
  Active against
       Half-life 
Drug FDA  status  Dose  Administration  (h)  P. aeruginosa MRSA  VRE  PRP
Ertapenem  Approved  1  g  qd  i.v.  4 – – – –
Doripenem   Approved  500 mg tid  i.v.  1  +  –  –  +
Biapenem  Phase II  300 mg bid  i.v.  1.03  +  –  –  +
Panipenem  Approved in Japan, China and Korea  0,5/0,5 g bid  i.v.  1.10–0.7  –  –  –  +
Tebipenem   Phase II  4 or 6 mg/kg bid  oral  U  –  –  U  +
Tomopenem   Phase II  700 mg  i.v.  1.7  +  +   
Razupenem   Phase II  U  i.v.  U  +  +  + 
Trinems    U U U – U  +/–  –
i.v.: intravenous; MRSA: methicillin-resistant S. aureus; PRP: penicillin-resistant pneumococci; U: unknown; VRE: vancomycin-resistant enterococci; +: active; –: non 
active; +/–: data only on small number of strains
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these agents may be indicated for nosocomial bacterial 
infections due to Gram-positive and Gram-negative 
bacteria, especially multiresistant Gram-positive cocci, 
including MRSA and vancomycin-resistant entero-
cocci (VRE) [52].
2. Another new compound is CS-023 (RO 4908463). It is 
more stable to hydrolysis by human DHP-I than 
meropenem or imipenem and has a broad spectrum of 
activity against Gram-positive and Gram-negative 
organisms. CS-023 seems more eﬀ   ective than imi-
penem and meropenem against MRSA, with an MIC 
of 4  mg/l. CS-023 is characterized by a low protein 
binding ratio, a feature which can be useful because 
the plasma active fraction achieves rapid equilibrium 
with intracellular ﬂ  uid [24].
3. ME 1036, previously named CP5609, is a novel 
parenteral carbapenem. In a recent study, the activity 
of ME1036 and comparators was evaluated against 
clinical blood culture isolates from patients with 
bacteremic community-acquired pneumonia (CAP) 
requir  ing hospitalization. Th  e results showed that 
ME1036 had excellent activity against CAP isolates 
causing serious invasive infections, including MRSA 
[53].
4. Razupenem (SMP-601) is a novel compound in phase 
II of evaluation. In a recent in vitro study, razupenem 
was found to be active against ESBL-producers, but its 
activity was signiﬁ  cantly reduced by AmpC enzymes 
and carbapenemases [54]. Razupenem’s activity can be 
improved by combining it with other antimicrobial 
agents:  In vitro studies have shown a synergistic 
activity with amikacin or ciproﬂ  oxacin  against  B. 
cepacia and S. marcescens [24].
5. Trinems, previously called tribactams, have a carba-
penem-related structure with a cyclohexane ring 
attached across carbon 1 and 2. One of these, 
sanfetrinem, is administered orally as a hexatil ester. 
Activity of sanfetrinem against P. vulgaris and K. 
oxytoca, which produce a potent class A β-lactamase, 
was reported in a study from 1998, but no recent 
studies of trinems have been published [55].
Conclusion
Infections due to MDR Gram-negative bacteria, such as 
ESBL or carbapenemase-producing Enterobacteriaceae 
and  A. baumannii or P. aeruginosa remain a serious 
problem in the hospital setting. Although some 
promising novel molecules are in the late stages of 
development, few new antibiotics have been advanced 
for the treatment of most of the ESKAPE pathogens. 
Among agents potentially active against Gram-negatives 
are novel cephalosporins, carbapenems and β-lactamase 
inhibitors.
Fifth generation cephalosporins have acquired activity 
against MRSA, but they oﬀ   er no advantage against 
Gram-negatives. Th   ey are inactive against MDR bacteria, 
and eﬃ   cacy of ceftaroline was less than that of aztreonam 
against P. aeruginosa. Some of the novel carbapenems are 
active against resistant Gram-positives, but when diﬃ   cult 
Gram-negatives are involved, their activity is similar to 
that of meropenem. Finally, β-lactamase inhibitors seem 
the most promising as they might restore the activity of 
already known β-lactams against β-lactamase-producing 
strains. However, their real clinical utility will be known 
only after results of large clinical trials are available.
Treating patients with infections due to resistant 
Gram-negative bacteria remains a serious challenge.
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